VivoSim Labs, Inc. Common Stock
VIVSStock
$0.61−53.65%52W
Market Cap$2.23M
P/E—
Div yield—
Beta1.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-71.21%
Price vs S&P 500 (4W)-27.70%
VGM Score35.35
Market Capitalization$2.23M
Earnings Surprise History
Q4 25-2.21est. -0.19
Analyst Recommendations
Sep 2021
Oct 2021
Nov 2021
Dec 2021
2.29
2.29
2.29
2.29
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VIVSVivoSim Labs, Inc. Common Stock | — | C | D | $0.61 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
VivoSim Labs Inc (formerly Organovo Holdings Inc) is a biotechnology company developing FXR314 for inflammatory bowel disease, validated through its proprietary 3D human tissue modeling platform. The company also generates revenue through liver toxicology screening services and drug safety profiling offerings for pharmaceutical and biotech clients across all stages of drug development.